Montanide ISA 51 VG

DRUG12 trials

Sponsors

National Cancer Institute (NCI), University of Southern California, Merck KGaA, Darmstadt, Germany, H. Lee Moffitt Cancer Center and Research Institute, Mayo Clinic

Conditions

Accelerated Phase Chronic Myelogenous LeukemiaAdult Acute Myeloid Leukemia With 11q23 (MLL) AbnormalitiesAdult Acute Myeloid Leukemia With Del(5q)Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)Adult Acute Myeloid Leukemia in Remission

Early Phase 1

Vaccine Therapy and Resiquimod in Treating Patients With Stage II-IV Melanoma That Has Been Removed By Surgery

CompletedNCT01748747

Mayo ClinicRecurrent Melanoma, Stage IIA Melanoma, Stage IIB Melanoma +5

Start: 2012-10-31End: 2017-03-30Updated: 2018-10-09

Phase 1

Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

CompletedNCT00004918

National Cancer Institute (NCI)Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia +4

Start: 1999-12-31Target: 69Updated: 2013-01-07

EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors

CompletedNCT01012102

Merck KGaA, Darmstadt, GermanyAdvanced Solid Tumors

Start: 2008-04-30End: 2011-09-30Updated: 2014-02-20

Multiple Class I Peptides & Montanide ISA 51 VG w Escalating Doses of Anti-PD-1 ab BMS936558

CompletedNCT01176461

H. Lee Moffitt Cancer Center and Research InstituteMelanoma (Skin)

Start: 2010-08-04End: 2016-12-12Updated: 2023-01-18

Vaccine Therapy and Basiliximab in Treating Patients With Acute Myeloid Leukemia in Complete Remission

CompletedNCT01842139

University of ChicagoAdult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q) +4

Start: 2011-12-05End: 2018-03-31Updated: 2018-03-09

Phase 2

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

CompletedNCT00085189

University of Southern CaliforniaCiliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Extraocular Extension Melanoma +14

Start: 2004-05-31End: 2007-09-30Updated: 2014-05-22

Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma

CompletedNCT00089063

National Cancer Institute (NCI)Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma +6

Start: 2004-06-30End: 2007-06-30Updated: 2015-04-15

Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma

CompletedNCT00923195

National Cancer Institute (NCI)Melanoma, Skin Cancer

Start: 2008-12-31End: 2011-08-31Updated: 2015-10-28

SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma

Active, not recruitingNCT02455557

Roswell Park Cancer InstituteGlioblastoma, Gliosarcoma

Start: 2015-05-04End: 2026-06-02Updated: 2026-03-30

Testing the SurVaxM Vaccine for Lung Cancer Prevention

Not yet recruitingNCT07169617

National Cancer Institute (NCI)Lung Carcinoma

Start: 2026-02-25End: 2027-09-30Target: 80Updated: 2026-03-30

Phase 3

Aldesleukin With or Without Vaccine Therapy in Treating Patients With Locally Advanced or Metastatic Melanoma

CompletedNCT00019682

National Cancer Institute (NCI)Recurrent Melanoma, Stage IIIA Skin Melanoma, Stage IIIB Skin Melanoma +2

Start: 1999-12-31End: 2011-05-31Updated: 2017-11-20

Unknown Phase

KLH Challenge to Explore the Human Immune Response

University of OxfordImmune Response

Start: 2023-03-01End: 2024-02-29Target: 39Updated: 2023-05-25

Related Papers

Intratumoral B cell and interferon signatures in newly diagnosed glioblastoma are associated with longer survival in patients treated with SurVaxM.

2025-10-09

RTID-04. A MULTICENTER, RANDOMIZED, CONTROLLED PHASE 2B TRIAL OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)

Neuro-Oncology2024-11-01

A multicenter, randomized controlled phase 2b trial of survivin vaccine SurVaxM plus adjuvant temozolomide for newly diagnosed glioblastoma (SURVIVE).

Journal of Clinical Oncology2024-06-014 citations

P07.09.B A RANDOMIZED PHASE 2B STUDY OF SURVIVIN VACCINE SURVAXM PLUS ADJUVANT TEMOZOLOMIDE FOR NEWLY-DIAGNOSED GLIOBLASTOMA (SURVIVE)

Neuro-Oncology2023-09-012 citations

Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma

Journal of Clinical Oncology2022-12-15139 citations

CTIM-26. PHASE II TRIAL OF SURVAXM PLUS TEMOZOLOMIDE FOR NEWLY DIAGNOSED GLIOBLASTOMA

Neuro-Oncology2022-11-01

Final data from the phase 2a single-arm trial of SurVaxM for newly diagnosed glioblastoma.

Journal of Clinical Oncology2022-06-016 citations

SurVaxM with standard therapy in newly diagnosed glioblastoma: Phase II trial update.

Journal of Clinical Oncology2019-05-2017 citations

Phase II trial of SurVaxM combined with standard therapy in patients with newly diagnosed glioblastoma.

Journal of Clinical Oncology2018-05-203 citations

The Reality of Precision Medicine in Metastatic Melanoma

Oncology Times2018-03-13

WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemia.

2018-01-1118 citations

WT1 Peptide Vaccine Is Able to Induce WT1-Specifc Immune Response with TCR Clonal Enrichment to Control Minimal Residual Disease in Patients with Myeloid Leukemia

Blood2016-12-022 citations

Abstract 4891: A mass spectrometry-based serum test to predict outcome of treatment with nivolumab: Analysis of samples taken during therapy

Cancer Research2016-07-153 citations

Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI).

Journal of Clinical Oncology2015-05-2015 citations

Updated survival, toxicity, and biomarkers of nivolumab with/without peptide vaccine in patients naive to, or progressed on, ipilimumab (IPI).

Journal of Clinical Oncology2014-05-2014 citations

gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma.

2011-06-01606 citations